Advertisement
Screener

uniQure N.V. (QURE) Accumulated Other Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

uniQure N.V. Accumulated Other Comprehensive Income

uniQure N.V. (QURE) had Accumulated Other Comprehensive Income of -$59.88 million as of 2026-03-31, per its 10-Q filed 2026-05-05.

Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-05-05

  • 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$59.88M.
  • 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$58.22M.
  • 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$58.74M.
  • 2025-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$58.90M.
Period endAccumulated Other Comprehensive Income (Loss), Net of TaxAccumulated Other Comprehensive Income (Loss), Net of Tax as first filed
2026-03-31-$59.88M
10-Q · filed 2026-05-05
2025-12-31-$58.22M
10-Q · filed 2026-05-05
2025-09-30-$58.74M
10-Q · filed 2025-11-10
2025-06-30-$58.90M
10-Q · filed 2025-07-29
2025-03-31-$53.80M
10-Q · filed 2025-05-09
2024-12-31-$52.80M
10-K · filed 2026-03-02
2024-09-30-$56.70M
10-Q · filed 2024-11-05
2024-06-30-$56.32M
10-Q · filed 2024-08-01
2024-03-31-$56.04M
10-Q · filed 2024-05-07
2023-12-31-$53.55M
10-K · filed 2025-02-27
2023-09-30-$58.56M
10-Q · filed 2023-11-07
2023-06-30-$52.44M
10-Q · filed 2023-08-01
2023-03-31-$52.49M
10-Q · filed 2023-05-09
2022-12-31-$58.30M
10-K · filed 2025-02-27
-$58.29M
10-K · filed 2023-02-27
2022-09-30-$93.00M
10-Q · filed 2022-11-02
2022-06-30-$67.63M
10-Q · filed 2022-08-08
2022-03-31-$39.31M
10-Q · filed 2022-05-02
2021-12-31-$28.90M
10-K · filed 2024-02-28
-$28.86M
10-K · filed 2022-02-25
2021-09-30-$17.88M
10-Q · filed 2021-10-25
2021-06-30-$4.59M
10-Q · filed 2021-07-26
2021-03-31$2.35M
10-Q · filed 2021-05-10
2020-12-31-$9.90M
10-K · filed 2023-02-27
$9.91M
10-K · filed 2021-03-01
2020-09-30$2.33M
10-Q · filed 2020-10-27
2020-06-30-$7.32M
10-Q · filed 2020-07-30
2020-03-31-$11.97M
10-Q · filed 2020-04-29
2019-12-31-$6.70M
10-K · filed 2022-02-25
-$6.69M
10-K · filed 2020-03-02
2019-09-30-$14.68M
10-Q · filed 2019-10-28
2019-06-30-$8.52M
10-Q · filed 2019-07-29
2019-03-31-$9.73M
10-Q · filed 2019-04-29
2018-12-31-$7.26M
10-K · filed 2020-03-02
2018-09-30-$5.49M
10-Q · filed 2018-11-06
2018-06-30-$4.69M
10-Q · filed 2018-08-08
2018-03-31-$1.31M
10-Q · filed 2018-04-30
2017-12-31-$3.80M
10-K · filed 2019-02-28
2017-09-30-$5.81M
10-Q · filed 2017-11-01
2017-06-30-$5.83M
10-Q · filed 2017-08-08
2017-03-31-$6.24M
10-Q · filed 2017-05-09
2016-12-31-$6.56M
10-K · filed 2018-03-14
2015-12-31-$6.83M
10-K · filed 2017-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Immunome Inc. (IMNM)United States$2.538B-9.45
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Zai Lab Ltd (ZLAB)$2.241B-113.34